Iohexol

Generic Name: Iohexol

Brand Names: Omnipaque, Oraltag

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₆I_₃N_₃O_₉

CAS Number: 66108-95-0

Unique Ingredient Identifier: 4419T9MX03

Background: Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.

Indication: Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Dosing Iodinated Contrast Media According to Lean vs. Total Body Weight

Phase 4

Completed

Conditions: Contrast Media Dosing

Interventions: Drug: Iohexol

First Posted Date: 2018-01-30

Last Posted Date: 2019-01-31

Lead Sponsor: Nova Scotia Health Authority

Target Recruit Count: 239

Registration Number: NCT03415997

Locations: 🇨🇦
Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada

Measurement of Iohexol Plasma Clearance in Patients Leaving ICU After Acute Renal Failure

Phase 3

Conditions: Acute Renal Failure

Interventions: Drug: IOHEXOL

First Posted Date: 2016-11-11

Last Posted Date: 2019-03-19

Lead Sponsor: University Hospital, Angers

Target Recruit Count: 150

Registration Number: NCT02961478

Locations: 🇫🇷
University Hospital, Tours, France
🇫🇷
Hospital center, Chartres, France
🇫🇷
Hospital, Le Mans, France

Clinical and Financial Impact of an Evidenced-Based Adhesive Small Bowel Obstruction Management Protocol

Not Applicable

Withdrawn

Conditions: Intestinal Obstruction

Interventions: Drug: Omnipaque
Drug: MD-Gastroview

First Posted Date: 2016-10-10

Last Posted Date: 2018-12-04

Lead Sponsor: The Guthrie Clinic

Registration Number: NCT02928458

Locations: 🇺🇸
The Guthrie Clinic, Sayre, Pennsylvania, United States

A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Metformin
Drug: Abemaciclib
Drug: Iohexol
Drug: Placebo

First Posted Date: 2016-08-30

Last Posted Date: 2019-01-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 40

Registration Number: NCT02884089

Locations: 🇺🇸
Dallas Clinical Research Unit, Dallas, Texas, United States

Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

Phase 2

Completed

Conditions: Acute Kidney Injury

Interventions: Drug: MB-102-- single dose of 4 µmol/kg
Drug: MB-102-- single dose of 130 mg
Drug: MB-102-- two doses of 130 mg 24 hours apart
Drug: MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart
Device: Brilliance (1 or 2 sensors)
Drug: Iohexol
Device: QuantumLeap
Device: Radiance
Device: Brilliance (2-part sensor)

First Posted Date: 2016-05-13

Last Posted Date: 2023-10-26

Lead Sponsor: MediBeacon

Target Recruit Count: 234

Registration Number: NCT02772276

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Riverside Clinical Research, Edgewater, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Uniformity of Oral Contrast Material in the Bowel

Completed

Conditions: Known or Suspected Abdominal Disease

Interventions: Drug: Barium
Drug: Diatrizoate
Drug: Iohexol

First Posted Date: 2015-09-04

Last Posted Date: 2019-12-11

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 900

Registration Number: NCT02542046

Locations: 🇺🇸
UCSF, San Francisco, California, United States

Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance

Phase 4

Completed

Conditions: HIV

Interventions: Drug: iohexol

First Posted Date: 2015-08-13

Last Posted Date: 2016-03-10

Lead Sponsor: Centre Hospitalier Universitaire de Saint Etienne

Target Recruit Count: 300

Registration Number: NCT02522338

Locations: 🇫🇷
CHU de SAINT-ETIENNE, Saint-etienne, France

Tenofovir Pharmacology in Older HIV Infected Individuals

Completed

Conditions: Aging
HIV

Interventions: Drug: iohexol

First Posted Date: 2014-12-01

Last Posted Date: 2016-09-26

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 45

Registration Number: NCT02304263

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

Phase 4

Completed

Conditions: HIV-1 Infection

Interventions: Drug: TVD
Drug: ATR
Drug: STB
Drug: RTV
Drug: ATV
Drug: ABC/3TC
Drug: Iohexol

First Posted Date: 2014-09-23

Last Posted Date: 2018-01-03

Lead Sponsor: Gilead Sciences

Target Recruit Count: 72

Registration Number: NCT02246998

Prediction of Excretion and Toxicity of High Dose Methotrexate in Children and Adolescents With ALL

Not Applicable

Completed

Conditions: ALL

Interventions: Drug: IOHEXOL

First Posted Date: 2014-05-08

Last Posted Date: 2021-08-02

Lead Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago

Target Recruit Count: 23

Registration Number: NCT02133599

Locations: 🇺🇸
Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy